Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-BO1202
- Development stage
- Discontinued
- Lead developer
- GoldenMed Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DCB-BO1202 is a small molecule drug developed by GoldenMed Biotechnology for the treatment of liver fibrosis, particularly in patients with chronic hepatitis B and intermediate hepatocellular carcinoma. The drug was investigated as an antifibrotic agent intended to alleviate liver fibrosis in the context of liver cancer and related hepatic conditions. Its precise mechanism of action remains undefined or unknown. Clinical development reached up to phase 2 trials; however, these were withdrawn prior to enrollment or discontinued, and no further development has been reported since early 2020[1][3][4]. The drug was administered orally in capsule form.
Beyond the preview
Go deeper on DCB-BO1202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-BO1202.